Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Martin P. Ogrodzinski"'
Autor:
Lei Yu, Shao Thing Teoh, Elliot Ensink, Martin P. Ogrodzinski, Che Yang, Ana I. Vazquez, Sophia Y. Lunt
Publikováno v:
Cancer & Metabolism, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with limited treatment options. Pyruvate kinase, especially the M2 isoform (PKM2), is highly expressed in PDAC cells, but its role in pancreatic cancer remains contro
Externí odkaz:
https://doaj.org/article/0dd57d2ce6dc48dd85df26dd36c615c7
Autor:
Jonathan P. Rennhack, Briana To, Matthew Swiatnicki, Caleb Dulak, Martin P. Ogrodzinski, Yueqi Zhang, Caralynn Li, Evan Bylett, Christina Ross, Karol Szczepanek, William Hanrahan, Muthu Jayatissa, Sophia Y. Lunt, Kent Hunter, Eran R. Andrechek
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
Mouse models are an essential tool in breast cancer research. Here, the authors present the genomic and transcriptomic profiles of two widely used mouse models, revealing parallels with the human disease specifically with metastasis and treatment res
Externí odkaz:
https://doaj.org/article/36cd74040a764c95a84c39189bb4072a
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Metastatic breast cancer is currently incurable. It has recently emerged that different metabolic pathways support metastatic breast cancer. To further uncover metabolic pathways enabling breast cancer metastasis, we investigated metabolic difference
Externí odkaz:
https://doaj.org/article/53858420900a422492563411a6134769
Supplementary figures and supplementary table titles.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::735ba4de00ac22ba8bdfa352e2e50385
https://doi.org/10.1158/0008-5472.22427493.v1
https://doi.org/10.1158/0008-5472.22427493.v1
Investigating metabolic rewiring in cancer can lead to the discovery of new treatment strategies for breast cancer subtypes that currently lack targeted therapies. In this study, we used MMTV-Myc–driven tumors to model breast cancer heterogeneity,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::722dac2ed9c50dd9e1f6cd716bad8fc8
https://doi.org/10.1158/0008-5472.c.6512697.v1
https://doi.org/10.1158/0008-5472.c.6512697.v1
Supplementary Table 1-8.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::466e1c82300730672dd8ededbf7482a1
https://doi.org/10.1158/0008-5472.22427487
https://doi.org/10.1158/0008-5472.22427487
Autor:
Deanna Broadwater, Hyllana C. D. Medeiros, Matthew Bates, Amir Roshanzadeh, Shao Thing Teoh, Martin P. Ogrodzinski, Babak Borhan, Richard R. Lunt, Sophia Y. Lunt
Publikováno v:
ACS applied materialsinterfaces. 14(48)
Photodynamic therapy (PDT) has the potential to improve cancer treatment by providing dual selectivity through the use of both photoactive agent and light, with the goal of minimal harmful effects from either the agent or light alone. However, curren
Publikováno v:
Cancer Research. 81:303-314
Investigating metabolic rewiring in cancer can lead to the discovery of new treatment strategies for breast cancer subtypes that currently lack targeted therapies. In this study, we used MMTV-Myc–driven tumors to model breast cancer heterogeneity,
Publikováno v:
Cellular Oncology. 43:1117-1127
Breast cancer is a heterogeneous disease with several subtypes that currently do not have targeted therapeutic options. Metabolomics has the potential to uncover novel targeted treatment strategies by identifying metabolic pathways required for cance
Autor:
Arul M. Chinnaiyan, Derek Dang, Nicholas K. Foreman, Jill Bayliss, Karin M. Muraszko, Fusheng Yang, Martin P. Ogrodzinski, Sriram Venneti, Debra Hawes, Li Jiang, Siva Kumar Natarajan, Andrew M. Donson, Drew Pratt, Stefan Sweha, Javad Nazarian, Chan Chung, Benita Tamrazi, Christopher Dunham, Hugh J. L. Garton, Joanna J. Phillips, Jason Heth, Sophia Y. Lunt, Deepak Nagrath, Brendan Mullan, Marcin Cieslik, Jin Heon, Marcel Kool, Stefan Bluml, Chao Lu, Abhinav Achreja, Andrey Korshunov, C. David Allis, Benjamin R. Sabari, Miriam Bornhorst, Matthew Pun, Juliette Hukin, Pooja Panwalkar, Olamide Animasahun, Andrea Griesinger, Stefan M. Pfister, Richard J. Gilbertson, Mariella G. Filbin, Alexander R. Judkins, Stephen Yip, Carl Koschmann
Publikováno v:
Sci Transl Med
Science translational medicine, vol 13, iss 614
Science translational medicine, vol 13, iss 614
Childhood posterior fossa group A ependymomas (PFAs) have limited treatment options and bear dismal prognoses compared to group B ependymomas (PFBs). PFAs overexpress the oncohistone-like protein EZHIP (enhancer of Zeste homologs inhibitory protein),